BioCryst Appoints Megan Sniecinski Chief Business Officer
July 01 2019 - 7:15AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the
appointment of Megan Sniecinski as chief business officer.
Ms. Sniecinski joins BioCryst from PTC
Therapeutics, where she served as senior vice president of business
operations and program management since June 2017. Over nearly five
years at PTC, Ms. Sniecinski played a key role in supporting the
diversified growth of PTC’s rare disease pipeline and
transformation into a global, fully-integrated biopharmaceutical
company.
“BioCryst has a growing portfolio of oral
medicines for rare diseases, including BCX7353 which is advancing
towards commercialization in several geographies. Megan brings
proven rare disease experience and leadership to help BioCryst
maximize opportunities to drive value for our programs around the
world,” said Jon Stonehouse, chief executive officer of
BioCryst.
“It is a privilege to join the BioCryst team at
this pivotal moment, and I am excited about the opportunity to help
BioCryst fulfill its mission to bring important life-changing oral
treatments to patients with rare diseases,” Sniecinski said.
In her recent role, Ms. Sniecinski led PTC’s
business development efforts, including the acquisition of Agilis
Therapeutics, an in-licensing commercial collaboration in Latin
America, and integration activities tied to the acquisition of
Emflaza®. In addition, she established and grew the program
management function responsible for advancing the clinical
development and commercialization of the pipeline. Ms. Sniecinski
joined PTC in September 2014 as vice president, business
operations, where she played a pivotal role in leading the
cross-functional launch integration team for the commercialization
of Translarna® and global expansion of PTC’s infrastructure.
Prior to joining PTC, she spent 12 years at
Merck in a diverse set of operational and strategic roles,
including director of strategic partnerships managing their
European vaccine joint venture, Sanofi Pasteur MSD.
Ms. Sniecinski received her B.S. in chemical
engineering from the University of Virginia and her M.B.A. from the
Wharton School of the University of Pennsylvania.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. BioCryst has several
ongoing development programs including BCX7353, an oral treatment
for hereditary angioedema, BCX9930, an oral Factor D inhibitor for
the treatment of complement-mediated diseases, galidesivir, a
potential treatment for Marburg virus disease and Yellow Fever, and
a preclinical program to develop oral ALK-2 inhibitors for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCryst’s actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: that developing BCX7353 may take longer
or may be more expensive than planned; that ongoing and future
preclinical and clinical development of BCX7353 may not advance as
expected; that future studies may not enroll the required number of
subjects or have positive results; and that the FDA, EMA or other
applicable regulatory agencies may require additional studies
beyond the studies planned, may not provide regulatory clearances,
may impose a clinical hold or may withhold market approval with
respect to BCX7353. Please refer to the documents BioCryst
files periodically with the Securities and Exchange Commission,
specifically BioCryst’s most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
all of which identify important factors that could cause the actual
results to differ materially from those contained in BioCryst’s
projections and forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024